Jpmorgan Chase & CO Cytokinetics Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Cytokinetics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,325,408 shares of CYTK stock, worth $79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,325,408
Previous 1,618,402
18.1%
Holding current value
$79 Million
Previous $76.1 Million
30.03%
% of portfolio
0.0%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding CYTK
# of Institutions
371Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.05 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$874 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$714 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$466 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$380 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.61B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...